Successful Treatment of Necrobiosis Lipoidica with Abrocitinib: A Case Report.

Introduction: Necrobiosis lipoidica (NL) is a rare granulomatous disease with no standardized treatment guidelines.

Case presentation: We present a case of a patient who experienced ulcerative NL of the left leg for 5 years, during which traditional treatments proved ineffective. The patient was administered oral abrocitinib at a dosage of 100 mg per day. After 2 weeks of treatment, the patient's skin lesions ceased exuding and began to show improvement. By the 10-week mark, the patient's symptoms had significantly improved, with the ulcer healing and no new lesions appearing. No adverse events were reported during the 4-month follow-up period.

Conclusion: Abrocitinib may represent a rapid and safe treatment option for patients with refractory localized NL. Further studies are warranted to confirm these findings and evaluate long-term efficacy.